Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 4
2010 1
2011 4
2012 3
2014 4
2015 1
2016 2
2017 6
2018 9
2019 7
2020 10
2021 13
2022 9
2023 7
2024 14
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. J Clin Oncol. 2025 Apr 10;43(11):1279-1288. doi: 10.1200/JCO-24-02266. Epub 2024 Dec 9. J Clin Oncol. 2025. PMID: 39652594 Free PMC article. Clinical Trial.
Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study.
Werner CM, Hecksteden A, Morsch A, Zundler J, Wegmann M, Kratzsch J, Thiery J, Hohl M, Bittenbring JT, Neumann F, Böhm M, Meyer T, Laufs U. Werner CM, et al. Among authors: bittenbring jt. Eur Heart J. 2019 Jan 1;40(1):34-46. doi: 10.1093/eurheartj/ehy585. Eur Heart J. 2019. PMID: 30496493 Free PMC article. Clinical Trial.
Advances in Lymphoma Molecular Diagnostics.
Kos IA, Thurner L, Bittenbring JT, Christofyllakis K, Kaddu-Mulindwa D. Kos IA, et al. Among authors: bittenbring jt. Diagnostics (Basel). 2021 Nov 23;11(12):2174. doi: 10.3390/diagnostics11122174. Diagnostics (Basel). 2021. PMID: 34943410 Free PMC article. Review.
[Lymphoma in rheumatic diseases].
Rubbert-Roth A, Bittenbring JT, Assmann G. Rubbert-Roth A, et al. Among authors: bittenbring jt. Z Rheumatol. 2017 Oct;76(Suppl 2):46-56. doi: 10.1007/s00393-017-0383-4. Z Rheumatol. 2017. PMID: 29330755 Review. German.
Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab.
Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, Altmeyer S, Bittenbring JT, Augsberger C, Ilieva-Babinsky K, Haskamp S, Beier F, Lischer C, Vera J, Lührmann A, Bertz S, Völkl S, Jacobs B, Steidl S, Mackensen A, Bruns H. Biedermann A, et al. Among authors: bittenbring jt. Haematologica. 2024 Dec 1;109(12):3928-3940. doi: 10.3324/haematol.2023.284795. Haematologica. 2024. PMID: 38934068 Free PMC article.
Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
Hoffmann MC, Cavalli G, Fadle N, Cantoni E, Regitz E, Fleser O, Klemm P, Zaks M, Stöger E, Campochiaro C, Tomelleri A, Baldissera E, Bittenbring JT, Zimmer V, Pfeifer J, Fischer Y, Preuss KD, Bewarder M, Thurner B, Fuehner S, Foell D, Dagna L, Kessel C, Thurner L. Hoffmann MC, et al. Among authors: bittenbring jt. J Clin Immunol. 2024 Jan 17;44(2):45. doi: 10.1007/s10875-023-01642-0. J Clin Immunol. 2024. PMID: 38231276 Free PMC article.
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Fürstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, Bittenbring J, Hebart H, Schöttker B, Illert AL, Graeven U, Stoltefuß A, Heinrich B, Eckert R, Fink A, Stumpf J, Fischer K, Al-Sawaf O, Simon F, Kleinert F, Weiss J, Kreuzer KA, Schilhabel A, Brüggemann M, Langerbeins P, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: bittenbring j. Blood. 2025 Mar 20;145(12):1282-1292. doi: 10.1182/blood.2024026685. Blood. 2025. PMID: 39883943 Clinical Trial.
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis.
Hoffmann MC, Fadle N, Regitz E, Kos IA, Cetin O, Lesan V, Preuss KD, Zaks M, Stöger E, Zimmer V, Klemm P, Assmann G, Pfeifer J, Bittenbring JT, Bewarder M, Vogt T, Pföhler C, Thurner B, Kessel C, Thurner L. Hoffmann MC, et al. Among authors: bittenbring jt. Immunol Lett. 2024 Dec;270:106926. doi: 10.1016/j.imlet.2024.106926. Epub 2024 Sep 10. Immunol Lett. 2024. PMID: 39265919 Free article.
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
Acker F, Chromik J, Tiedjen E, Wolf S, Vischedyk JB, Makowka P, Enßle JC, Kouidri K, Sebastian M, Steffen B, Oellerich T, Serve H, Neubauer A, Schäfer JA, Bittenbring JT. Acker F, et al. Among authors: bittenbring jt. Eur J Haematol. 2024 Nov;113(5):623-630. doi: 10.1111/ejh.14278. Epub 2024 Jul 18. Eur J Haematol. 2024. PMID: 39023132
81 results